Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.
Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.
The tragedy in Newtown should bring gun owners and opponents together.
Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.
Medical innovation is increasing but ever-escalating drug prices aren't sustainable.
TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.
Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.
A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.
The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.
An FDA decision expected this week could easily go against United Therapeutics.